---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-027759"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:11:34.070134+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Acadia Q4 net income $143.7M; FY2024 revenue $957.8M (+32%); guides FY2025 rev $1.03-1.095B

## Summary
- FY2024 total net product sales $957.8M, up 32% YoY; NUPLAZID $609.4M (+11%), DAYBUE $348.4M (+97%).
- Q4 net income $143.7M ($0.86 EPS) vs $45.8M ($0.28 EPS) in Q4 2023; includes $146.5M PRV sale gain.
- FY2024 net income $226.5M ($1.37 EPS) vs net loss of $61.3M ($0.37 loss per share) in FY2023.
- FY2025 guidance: total revenue $1.03-1.095B; NUPLAZID $650-690M; DAYBUE $380-405M; R&D $310-330M; SG&A $535-565M.
- Cash and investments $756.0M at Dec 31, 2024, up from $438.9M; EMA submission for trofinetide completed.

## SEC filing metadata
- accession: 0000950170-25-027759
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017025027759/0000950170-25-027759-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017025027759/acad-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-027759
- JSON: https://secwatch.observer/filing/0000950170-25-027759.json
- Plain text: https://secwatch.observer/filing/0000950170-25-027759.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.